The Australian sharemarket has extended a late end of year rally, sidestepping a tech selloff in the US overnight as volumes ...
Zacks.com on MSN21h
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This ...
The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...
Email Alerts for: Current price: $2.63 Market cap: $3.93bn Current price: $3.01 Current price: $2.31 Current price: $3.69 ...
These shares are having a better day than most today. But why? The post Why Avita Medical, GenusPlus, Mesoblast, and Polynovo ...
Regenerative medicine company Mesoblast Ltd. received an early Christmas present from the FDA for approval of its allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy, Ryoncil ...
Mesoblast Limited, global leader in allogeneic cellular medicines for inflammatory diseases, announced the Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L) as the first mesenchymal ...
Jefferies downgraded Mesoblast (MESO) to Hold from Buy with a price target of A$2.30, up from A$1.10. The firm updated the company’s for the ...
GEN presents data compiled by Morningstar's Morningstar Direct asset management platform for StockWatch of the top five ...
Meanwhile, synthetic gel aids in recovery after spinal surgery; Pittsburgh researchers create helper robots for people with ALS; a study finds nerve stimulation is effective against ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback